New insider activity at Ardelyx ( (ARDX) ) has taken place on January 9, 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ardelyx’s Chief Patient Officer, Laura A. Williams, has recently trimmed her holdings in the company by selling 50,000 shares of Ardelyx stock in a transaction valued at $348,500, signaling a notable movement among the company’s top executives in the open market.
Recent Updates on ARDX stock
Over the last 24 hours, Ardelyx has seen a wave of bullish analyst revisions following its Q4 pre-release and updated long-term guidance, which highlighted much stronger prospects for its IBS-C drug Ibsrela. Management now projects Ibsrela revenue of $410M–$430M in 2026 and about $1B in 2029, a much faster ramp than previously assumed by several firms and well ahead of prior consensus. Citi’s higher target is driven by the company’s more aggressive timeline to reach $1B in annual Ibsrela sales, implying faster market penetration. BTIG’s revision reflects confidence in Ibsrela’s path to over $1B in peak sales supported by robust 2025 performance, underpenetrated IBS-C market opportunity, initiation of a new Phase 3 CIC trial, extended intellectual property protection through 2041, growing Xphozah revenue, a progressing pipeline, and a solid cash position that should fund ongoing development. Piper Sandler’s upgrade and target increase follow the Q4 and guidance update, emphasizing that Ibsrela’s FY26 outlook markedly exceeds prior expectations and that the earlier-than-expected $1B 2029 revenue target materially improves the long-term growth profile. Raymond James’ higher target is tied to what it characterizes as a uniformly positive update, with the same FY26 and FY29 Ibsrela revenue guide seen as a catalyst for a potential re-rating of the stock, especially heading into a key competitor conference. These developments collectively underscore growing Street confidence in Ardelyx’s commercial trajectory and long-term earnings power, which has been the primary driver of the recent positive reassessment of the shares.
Spark’s Take on ARDX Stock
According to Spark, TipRanks’ AI Analyst, ARDX is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, negative operating cash flow, and higher leverage). Offsetting this, technicals are bullish with strong trend and momentum, and the latest earnings call was positive with raised IBSRELA guidance and a strong cash position. Valuation remains a concern given the negative P/E and no indicated dividend support.
To see Spark’s full report on ARDX stock, click here.
More about Ardelyx
YTD Price Performance: 20.07%
Average Trading Volume: 3,809,027
Technical Sentiment Signal: Buy
Current Market Cap: $1.42B